NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10816	Companies
234400	Keywords
163253	Articles
125406	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 08/08/2024 at 12:30, 2 years ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides provides update on clinical program & strategy for novel antiviral drug NV-387, targeting Influenza, COVID, RSV & more. Broad-spectrum potential discussed

NanoViricides NV-387 Clinical Program Antiviral Drug Broad-spectrum
BRIEF

published on 08/01/2024 at 12:35, 2 years ago

NanoViricides' Broad Spectrum Technology Promises New Approach in Viral Therapy

NanoViricides NV-387 Clinical Trials Antiviral Therapy Market Potential
BRIEF

published on 08/01/2024 at 12:35, 2 years ago

La technologie à large spectre des nanoviricides promet une nouvelle approche en matière de thérapie virale

NanoViricides NV-387 Essais Cliniques Potentiel De Marché Thérapie Antivirale
PRESS RELEASE

published on 08/01/2024 at 12:30, 2 years ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
NanoViricides, Inc., reports on independent research highlighting NV-387's broad-spectrum action in viral therapy, potentially revolutionizing antiviral treatment strategies

NV-387 NanoViricides Inc. Antiviral Nanomedicines Broad-spectrum Action Viral Therapy
BRIEF

published on 07/24/2024 at 12:35, 2 years ago

NanoViricides Highlights NV-387's Potential Against COVID-19

COVID-19 NanoViricides NV-387 Clinical Trials Antiviral
BRIEF

published on 07/24/2024 at 12:35, 2 years ago

Les nanoviricides mettent en évidence le potentiel du NV-387 contre le COVID-19

NanoViricides NV-387 Essais Cliniques COVID 19 Antiviral
PRESS RELEASE

published on 07/24/2024 at 12:30, 2 years ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
NanoViricides, Inc. showcases strong safety and effectiveness of lead drug NV-387 against coronaviruses, potentially filling the gap in COVID treatments. Seeking collaborations for regulatory approvals

NanoViricides NV-387 Drug Development Coronaviruses COVID Treatments
BRIEF

published on 07/11/2024 at 12:35, 2 years ago

NanoViricides Plans Next Phase of Clinical Trials for Broad-Spectrum Antiviral NV-387

NanoViricides NV-387 Clinical Trials Antiviral Drug Broad-spectrum
BRIEF

published on 07/11/2024 at 12:35, 2 years ago

NanoViricides prévoit la prochaine phase d'essais cliniques pour l'antiviral à large spectre NV-387

NanoViricides NV-387 Essais Cliniques Médicament Antiviral Large Spectre
PRESS RELEASE

published on 07/11/2024 at 12:30, 2 years ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
NanoViricides, Inc. discusses development program for antiviral drug NV-387 effective against various respiratory infections, advancing towards human clinical trials

NV-387 Clinical Trials Respiratory Infections NanoViricides Inc. Antiviral Drug

Accesswire

Published on 08/10/2026 at 15:30, 4 hours 51 minutes ago

Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Published on 08/10/2026 at 15:25, 4 hours 56 minutes ago

Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Published on 08/10/2026 at 14:30, 5 hours 51 minutes ago

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Published on 08/10/2026 at 13:30, 6 hours 51 minutes ago

Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Published on 08/10/2026 at 13:00, 7 hours 21 minutes ago

Alaska Energy Metals Announces Drilling Program for the Mcbride Prospect, Angliers-Belleterre Project, Quebec, Canada

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 19:35, 46 minutes ago

Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Published on 08/10/2026 at 19:00, 1 hour 21 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Published on 08/10/2026 at 18:29, 1 hour 51 minutes ago

Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/10/2026 at 17:50, 2 hours 31 minutes ago

Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report
Published on 08/10/2026 at 17:38, 2 hours 43 minutes ago

PATRIZIA delivers strong earnings growth with EUR 42.7m EBITDA (+46.6% y-o-y) in H1 2026

Les Echos

Published on 08/10/2026 at 18:00, 2 hours 21 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 hours 21 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 2 hours 36 minutes ago

Weekly share buyback
Published on 08/10/2026 at 17:45, 2 hours 36 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 8 hours 27 minutes ago

GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026

View all LES ECHOS COMFI WIRE